Sanovas is redefining intervention with access, imaging, measurement technologies, auto-pathology recognition (AI) and telehealth that enables physicians to perform MORE interventional procedures, in MORE places, MORE affordably. The company is dedicated to developing the full continuum of best-in-class minimally invasive diagnostic and therapeutic technologies and solutions that are affordable, accessible, and safe across multiple procedures for many medical specialties.
The company’s mission is to rapidly improve global healthcare access for millions in the world as well as in the U.S., who are currently underserved. Advanced minimally invasive diagnostic and therapeutic procedures will be available to millions of healthcare facilities, large and small.
In summary, Sanovas is a company solving big healthcare market access, safety, quality, and cost problems while growing the minimally invasive interventions market. Working with physicians and hospital executives and other healthcare specialists, Sanovas is leading the way in making minimally invasive interventions more accessible, affordable, and safe around the world.
Minimally Invasive Surgery (MIS), the ability to perform medical interventions through small “keyholes” versus large, open incisions, has flourished over the past 20 years. Now, however, the necessity to go farther and do more has created the opportunity for innovation and technology to redefine MIS and to make what is now possible accessible, affordable, and safe for more people.
Sanovas’ core micro technology platform provides:
MicroCam™ imaging technology is expected to reduce endoscopy costs by up to 80% and eliminate as much as 90% of the associated capital equipment requirements for hospitals and healthcare facilities. Sanovas’ affordable imaging cameras, scopes, and other devices may be the first of their kind that an underdeveloped country can afford, allowing diagnosis and treatments that were not previously available.
Sanovas Inc. was founded with the humanitarian inspiration to treat and cure lung cancer and related pulmonary diseases. Diagnostic and surgical procedures on the lungs have been difficult and complex for physicians as they are recognized as the last frontier in interventional medicine.
Small, tight spaces of the airways are constantly moving in and out. Unlike heart surgery, airflow (respiration) cannot be turned off or rerouted during a surgical procedure.
The technology that needed to be developed for this most difficult challenge has led Sanovas to develop improvements in an entire range of core microtechnologies for medical specialties.
The Sanovas product portfolio is built on a platform of core micro technologies. These access, imaging, measurement, diagnostic, and therapeutic technologies have application across multiple products and medical specialties. The Sanovas core micro technologies contribute to making advanced diagnostic and therapeutic interventions accessible, affordable, and safe in small anatomic spaces. These core micro technology platforms are:
Sanovas' commercial business is segmented into business units that leverage cost-effective delivery of advanced diagnostic and therapeutic interventions enabled by our core micro technology platforms. Each business unit focuses on a specific target audience. These current business units are